Compare TransMedics Group Inc (TMDX) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs VICI Properties Inc — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while VICI Properties Inc trades at $25.3 (market cap $27.82B). The key difference: VICI Properties Inc is far larger — about 9.1× TransMedics Group Inc's market cap, and VICI Properties Inc pays a 7.28% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | VICI | |
|---|---|---|
Market Cap | $3.06B | $27.82B |
Sector | Technology | Real Estate |
52-Week High | $150.42 | $33.16 |
52-Week Low | $61.99 | $25.23 |
Enterprise Value | $3.46B | $45.38B |
Dividend Yield | — | 7.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
VICI trades at $25.29, down 0.51% today, with a bearish technical signal from moving averages but oversold RSI readings. The stock offers a high dividend yield above 7%, supported by strong profitability margins (net income margin 67.5% in 2025) and a low P/E of 9.79. Recent corporate actions include a dividend increase to $0.46 per share and the appointment of a new independent director, reflecting steady governance.
Outlook remains positive with a consensus price target of $29.29 (16% upside), driven by stable cash flows and REIT income appeal. Risks include earnings volatility (two recent EPS misses) and acquisition yield pressures. Institutional sentiment is bullish (77% buy ratings), but technical weakness near support at $25 requires monitoring for entry opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
